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Abstract
Purpose of review—In this article we will discuss the current understanding of bone pain and 
muscle weakness in cancer patients. We will describe the underlying physiology and mechanisms 
of cancer-induced bone pain (CIBP) and cancier-induced muscle wasting (CIMW), as well as 
current methods of diagnosis and treatment. We will discuss future therapies and research 
directions to help patients with these problems.
Recent Findings—There are several pharmacologic therapies that are currenly in pre-clinical 
and clinical testing that appear to be promising adjuncts to current CIBP and CIMW therapies. 
Such therapies include resiniferitoxin, which is a targeted inhibitor of nociptive nerve fibers, and 
selective androgen receptor modulators, which show promise in increasing lean mass.
Summary—CIBP and CIMW are a significant causes of morbidity in affected patients. Current 
management is mostly palliative; however, targeted therapies are poised to revolutionize how these 
problems are treated.
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INTRODUCTION
With the rising incidence of cancer worldwide and advances in treatment, there has been an 
increase in the number of patients living with debilitating complications of chronic cancer. 
The most common cause of cancer-induced pain arises from bone metastases.[1] Of 
advanced cancer suffers, 60–84% are estimated to experience varying degrees of bone pain.
[2] Cancer-induced bone pain (CIBP) involves both neuropathic and inflammatory pain 
pathways, associated with tumor, stroma, and adjacent tissues, including peripheral and 
central nerves.[1]
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The establishment of animal models have helped to elucidate the relationship between 
tumor, pain and neuronal interactions.[3] This in turn has helped in our understanding of this 
disease process and is helping to develop new targetted therapies to treat CIBP. Evaluation of 
patients with CIBP requires a comprehensive assessment of their current health status 
including the development of a trusting relationship, obtaining a thorough history of the 
pain, understanding the doses and durations of pain medications used to date, evaluation of 
psychological status, performing a thorough physical exam including neurologic exam, and 
reviewing diagnostic studies and laboratory findings. The ultimate goal is to develop an 
individualized treatment plan to obtain an acceptable quality of life.[2]
1.0 BONE PAIN IN CANCER
Myeloid leukemia, prostate, lung, and breast cancers are the malignancies most commonly 
associated with bone metastases. Although methods such as magnetic resonance imaging 
(MRI), computed tomography (CT) scan and 18-fluorodeoxyglucose positron emission 
tomography (FDG-PET/CT) may provide early diagnosis of bone metastases, the current 
treatment options remain mostly palliative and thus are generally reserved for patients once 
they become symptomatic. The importance of addressing symptoms must not be 
understated, as pain will drastically decrease quality of life (QoL), and furthermore, there is 
mounting evidence that survival for cancer patients is linked to symptom control.[4].
1.1 CLINICAL PRESENTATION AND ASSESSMENT OF CIBP
CIBP is one of the leading causes of significant morbidity in cancer patients. Early diagnosis 
and therapy are important to improve QoL. CIBP may present with symptoms that range 
from dull, vague, persistent pain to intermittent, sharp, severe pain and is generally 
exacerbated by physical activity. A careful history is required in making the diagnosis, 
whereas physical examination aided by various diagnostic modalities helps in confirmation 
of the pain’s etiology. CIBP usually presents gradually and is progressive. It is usually 
related to weight bearing or movement, and develops into shooting neuropathic pain and 
pathologic fractures. Commonly involved sites are vertebrae, pelvis, femur, ribs and skull.[2] 
Patients also describe bouts of severe, intermittent pain despite analgesic intervention, called 
breakthrough pain, which is a sign of inadequate pain management.[5]
1.2 DIAGNOSTIC APPROACH TO BONE METASTASES
Biochemical findings, like elevated serum calcium, decreased renal function, increased urine 
calcium and urine hydroxyproline (an indirect measure of increased bone turn over), serum 
alkaline phosphatase level, and decreased osteocalcin (especially in multiple myeloma) aid 
in the diagnosis of bone involvement in cancer patients. Also, electrocardiography may 
demonstrate a shortened QT interval secondary to hypercalcemia. Diagnostic imaging with 
plain films (x-ray), bone scintigraphy (BS), MRI, CT scan and FDG-PET/CT are commonly 
used techniques. The diagnostic strategy is greatly influenced by pathology, available 
imaging modalities, and location of skeletal metastasis. A recent study from Denmark 
compared the diagnostic accuracy of the above modalities and with pathologic reports of 
bone biopsies. The sensitivity of MRI and FDG-PET/CT was better than CT, whereas CT 
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had higher specificity than FDG-PET/CT. For osteolytic and mixed lesions MRI and FDG-
PET/CT were more sensitive as compared to CT and vice versa for osteosclerotic lesions. 
For spinal lesions, MRI had the highest sensitivity (92%) and specificity (80%); whereas for 
non-spinal lesions, FDG-PET/CT had the highest sensitivity (97%) and specificity (69%), 
but was not significantly different from MRI or CT. X-ray and BS were found to be inferior 
in diagnostic accuracy when compared to the other modalities.[6] In the case of an equivocal 
bone lesion in patients with hepatocellular carcinoma, single-photon emission computed 
tomography (SPECT) combined with spiral CT is found to be more accurate.[7]. 18F-NaF/
FDG-PET/CT was found to be superior to whole body MRI and BS for evaluation skeletal 
disease in breast and prostate cancer, since it detects extra-skeletal disease which can 
significantly alter disease management.[8, 9].
There are inherent biologic and physical factors limiting the effectiveness of imaging 
technologies. Specificity is diminished by an inability to distinguish between metastatic 
tumor burden versus joint degeneration. Flare from increased radiotracer uptake in 
previously diagnosed, new, or undetected lesions after initiating therapy may also make 
image interpretation difficult. Scans are used to assess disease progression and response to 
therapy. However, by monitoring bone activity, a pleotropic drug which affects bone 
remodeling rather than cancer cells may lead to misinterpretation of results.[10] Scan 
duration, resolution and artifactual uptake are challenges which can be overcome by more 
disease-specific targeted imaging techniques.[10]
1.3 PATHOPHYSIOLOGY
Understanding the molecular aspects of the pathogenesis of bone metastases and subsequent 
complications associated with their development underlies the basis of developing targeted 
therapies. The development of tumor metastases involves sequential steps, including 
progressive tumor growth, vascularization, invasion, detachment, embolization, survival in 
circulation, arrest at site of metastasis, extravasation, evasion of host defense, and 
progressive growth.[11] There is disruption of the fundamental balance between osteoclasts, 
osteoblasts, and signaling pathways involved in controlling bone density. Osteoclasts and 
precursor osteoclasts express receptor activator of nuclear factor kappa β (RANK), ligand of 
RANK (RANKL) - the key stimulator of bone resorption, and cytokine osteoprotegerin 
(OPG), which inhibits bone resorption.[12, 13]
a. Osteolytic Metastases
Osteolytic metastases are more common than osteoblastic metasteses and are seen with 
breast and lung tumors and multiple myeloma. Metastatic cells produce many factors, such 
as parathyroid hormone related peptide (PTHrP), TGF-β, interleukins (ILs)- IL-1, IL-6, 
colony stimulating factor-1 (CSF-1), insulin-like growth factor-1 (IGF-1), prostaglandins, 
CXCR4, which interact with osteoblasts to modulate the RANK-RANKL pathway to 
stimulate osteoclast precursors and alter the microenvironment, starting the vicious cycle of 
osteolysis.[14]
PTHrP is known to be one of the most critical mediators of osteoclastic activation. It works 
by binding PTH-receptor 1 (PTH-R1), inducing RANKL expression and OPG 
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downregulation in osteoblasts.[12, 14–18] Deleted in Liver Cancer 1 (DLC1), a metastasis 
suppressor gene, acts through its RhoGTPase activating protein (RhoGAP) activity, which 
inhibits RhoA, RhoB, RhoC and cell division cycle 42 (cdc42) via hydrolysis of GTPase 
bound GTP.[19] DLC1-Rho signaling regulates osteoclastogenesis by blocking TGF-β-
induced PTHrP secretion, and thus regulates metastatic colonization of circulating breast 
cancer cells. Experiments in mice have demonstrated enhanced bone metastasis in breast 
cancer cells lacking DLC1.[20] Data suggest that chemokine receptor CXCR4/CXCR7 and 
its ligand CXCL12/stromal derived factor-1α(SDF-1α) are highly expressed in skeletal 
metastases, especially in breast cancer cells.[15, 16, 21] Hypoxic microenvironments in 
bone (pO2 1–7%) stimulate hypoxia-inducible factor-1α(HIF-1α). HIF-1α stimulates 
hypoxia response elements (HRE) and multiple factors, such as vascular endothelial growth 
factor (VEGF)[22], IGF-2, and CXCR4, have been implicated in metastatic bone 
colonization.[15] Hypoxia and constitutively active HIF-1α in MDA-MB-231 human breast 
cancer cells was found to be associated with increased osteoclast formation and decreased 
osteoblast differentiation, thereby promoting progression of bone metastasis. [23] Tumor 
hypoxia enhanced expression of connective tissue growth factor (CTGF) and IL-11, which 
initiate invasive angiogenesis and expression of hypoxia-associated genes, have been shown 
to contribute to the development of bone metastasis in hepatocellular carcinoma.[24]
b. Osteoblastic Metastases
Endothelin-1 (ET-1) growth factor induces osteoblastic proliferation via the ET-1A receptor 
(ETAR), as well as enhances expression of bone specific proteins osteocalcin, osteonectin, 
and alkaline phosphatase. Osteoblastic metastases from prostate and breast carcinoma are 
found to high levels of ET-1 and ETAR. The ETAR antagonist ABT-627 (Atrasentan) has 
been shown to block development of macroscopically evident osteoblastic metastasis.[15, 
25, 26]
The Wnt family are cysteine-rich glycoproteins that mediate bone emybronic bone 
development and promote adult bone formation. They have autocrine and paracrine effects, 
enhancing proliferation and induction of osteoblastic activity in prostate cancer bone 
metastasis. Metastatic prostate cancer cells express the Wnt inhibitor dickkopf-1 (DKK-1) 
early in the development of skeletal metastasis. As disease progresses, DKK-1 expression 
decreases and unmasks Wnt osteoblastic activity, leading to osteosclerosis at metastatic 
sites. The initial osteolytic phase, mediated by DKK-1, RANKL, and PTHrP, causes an 
altered tumor environment. This leads to hypoxia and production of HIF-1α, VEGF and 
ET-1, thereby promoting osteoblastic activity.[27] A recent study showed significant 
inhibition of ERα signaling in prostate cancer cells in vivo leading to inhibition of 
osteoblastic lesions and formation of lung metastases.[28]
c. Hypercalcemia
Hypercalcemia is commonly seen in advanced stages of cancer.[29] PTHrP, which is 
secreted by various cells, mediates nearly 80% of malignancy-related hypercalcemia.[30] 
PTHrP acts on the same receptors as PTH in the bone, kidneys and intestine, increases bone 
resorption via RANKL, and increases calcium absorption in the intestine and reabsorption in 
the kidneys, leading to hypercalcemia.[31] Excessive calcium release from bone coupled 
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with abnormal retention of calcium in circulation and osteolytic metastases accounts for 
approximately 20% of malignancy-related hypercalcemia.[29, 30] Studies also demonstrate 
that in lymphomas and some other ovarian germ cell tumors, increased activity of 1α-
hydroxylase and formation of 1,25-dihydroxycholecalciferol contributes to hypercalcemia.
[29, 30]
d. Mechanism of Pain
While a multitude of factors contribute to pain caused by bone metastases, the exact 
mechanisms still remain unclear. The mechanisms hypothesized to cause bone pain are: a. 
stimulation of endosteal nerve endings resulting in destruction of bone tissue and release of 
chemical agents such as prostaglandins, bradykinin, substance P, and histamine; b. 
increasing stretch of the periosteum by enlarging tumors; c. fractures; and d. growth of 
tumor into surrounding tissues, especially nerves.[32]
Cancer cells promote proliferation and activity of bone-destroying osteoclasts via activation 
of the RANKL/RANK pathway. Osteoclast-mediated resorption of bone occurs through 
formation highly acidic resorption ‘pits’ between the osteoclasts and bone, stimulating the 
TRPV1 and ASIC3 channels expressed by a significant population of nerve fibers that drive 
bone cancer pain.[33–35] Mineralized bone undergoes loss of mechanical strength and 
stability due to the action of osteolytic and osteoblastic tumors. Extensive remodeling due to 
these effects can result in distortion from what would otherwise be an innocuous mechanical 
stress, activating the mechanosensitive nerve fibers of the bone.[33]
Cancer cells and surrounding stromal cells secrete a variety of factors (for example: 
bradykinin, endothelins, IL-6, nerve growth factor (NGF), and proteases), which sensitize or 
directly excite primary afferent neurons.[33] Studies have shown NGF to activate Trk-A-
expressing sensory neurons directly, sensitizing TRPV1. The retrograde transport of NGF/
TrkA complexes into nociceptor neurons induces and increases synthesis of the 
neurotransmitters substance P and calcitonin gene-related peptide, transcription factors 
(ATF3), and sodium channels, thus modulating supporting cells in dorsal root ganglia 
(DRG) and peripheral nerves.[33, 36–38]
Murine models of sarcoma, breast, and prostate derived bone cancer have shown active and 
pathological sprouting and neuroma formation by sensory and sympathetic nerve fibers that 
innervate the skeleton.[33] This sprouting requires NGF and sustained administration of 
anti-NGF or Pan Trk (Trk A, Trk B, Trk C). Inhibition of pathological sprouting and 
neuroma-like structure formation in sensory nerve fibers significantly inhibits pain 
generation.[33, 39–42] Several animal studies have shown sensitization of the spinal cord 
innervating the tumor bearing tissues by modification in levels of dynorphin, ATF3, 
astrocytes, microglia, c-Fos expression and substance P internalization.[33, 43]
1.4 THERAPEUTIC MANAGEMENT OF CIBP
The approach towards management of CIBP involves gradual escalation from conservative 
to interventional techniques based on response and severity of symptoms.
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I. NON-PHARMACOLOGICAL APPROACH
The International Association for the Study of Pain defines pain as “an unpleasant sensory 
and emotional experience associated with actual or potential tissue damage, or descrbied in 
terms of such damage.” As such, cancer patients’pain is highly influenced by various 
psychological and social factors. Interventions such as meditation, relaxation techniques, 
guided imagery, hypnosis, cognitive behavioral coping skills, therapist contact[44] form an 
essential part of a conjoint palliative approach.[45]
II. PHARMACOTHERAPY
Most physicians treat CIBP according to the World Health Organization’s three-step ladder 
for cancer pain relief. This entails treating pain initially with a non-opiod medications, then 
escalating to opiods of increasing strength, and adding adjuvant therapies as needed as the 
patient’s pain increases.[45]
a. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)—NSAID mechanism of action 
is via the inhibition of the cyclooxygenase [COX (COX1 & COX2)] enzymes, which 
catalyze formation of prostaglandins from arachidonic acid as a critical step in the 
inflammatory response.[3] COX-2 is highly expressed in tumor cells and peripheral 
macrophages around tumor cells, where it is involved in tumor cell invasion, migration and 
metastasis. COX-2 has been shown to reduce tumor burden in sarcoma-bearing bones in 
addition to reducing pain and bone destruction in an in vivo murine model.[46] However, 
various phase II and III trials found increased cardiovascular events from COX-2 inhibition, 
thereby tempering the enthusiasm for use of COX-2 inhibitors in cancer patients.[47, 48]
b. Opioids—Opioids are one of the most frequently used analgesics for CIBP. They act on 
opioid G-protein coupled receptors (μ, κ, and δ), inhibiting substance P release in the dorsal 
horn.[47] Opiods are used by nearly 80% of cancer patients for pain control. Sustained and 
on-demand formulations are used in conjuction to provide pain suppression and 
breakthrough pain relief respectively. Opiods have limiting side effects of nausea, itching 
constipation, tolerance, development of addiction, and respiratory depression.[3, 45] 
Furthermore, a study in a murine model demonstrated prolonged exposure to opiods might 
worsen CIBP, accelerate bone loss, and increase incidence of spontaneous fractures.[49] 
Opioids synergize with NSAIDs, benzodiazapines, and anti-depressant therapies, which may 
improve pain control and limit the need for opioids. The concomitant use with 
benzodiazepines risks exacerbating some of the deleterious side effects of opioids, 
particularly respiratory depression. Increasingly, combination of low dose pregabalin-
antidepressants with opioids has been found to be effective in the management of 
neuropathic CIBP.[50]
c. Bisphosphonates—Older generation bisphosphonates (i.e. clodronate and etidronate) 
were metabolized by osteoclasts into cytotoxic ATP analogs, interfering with mitochondrial 
membrane, potentially leading to osteoclast apoptosis. Newer generation nitrogen-
containeing intravenous bisphosphonates (i.e. pamidronate, ibandronate and zoledronate) are 
internalized by osteoclasts and inhibit the farnesyl pyrophosphate (FPP) synthase enzyme, 
active in prenylation of several GTPases involved in bone resorption. This causes 
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accumulation of isopentyl pyrophosphate and adenosine monophosphate, which conjugate to 
form an endogenous ATP analogue that inhibits mitochondrial adenine nucleotide 
translocase (ANT) and leads to osteoclast apoptosis.[51] Multiple studies have demonstrated 
efficacy of bisphosphonates in reducing skeletal complications and CIBP.[52] Zoledronate, 
in addition to reducing skeletal morbidity, has been reported to have direct antitumor 
properties: induction of tumor cell apoptosis, inhibition of cancer cell invasion[53], limiting 
metastatic outgrowth in visceral tissues[51, 54], and causing decrease in VEGF levels, 
thereby potentially slowing bone disease.[55, 56] While bisphosphonates are useful 
adjuvants in the treatment of CIBP, they do not themselves block pain, and must be used in 
conjuction with other therapies.[57] Intravenous bisphosphante therapy requires dental 
evaluation and follow-up to monitor for osteonecrosis of the jaw as well as renal monitoring 
and caution for patients with kidney disease or who are taking other nephrotoxic agents.[51]
d. Novel Targeted Therapies
Denosumab: Denosumab is a monoclonal antibody against RANKL. It is a potent inhibitor 
of osteoclast-mediated bone resorption. Multiple phase III trials have shown an increase in 
bone mineral density, a decreased risk of fractures, and a delay in skeletal-related events 
(SRE) with use of denosumab [15]; however, data regarding overall survival remains 
controversial.[58] Denosumab was superior to zolendronate in preventing SRE in patients 
with advanced disease regardless of performance status and disease extent.[59]
Atrasentan: ET-1 receptor sensitization and/or activation has been associated with 
hyperalgesia of CIBP. The ET1A receptor antagonist atrasentan is under phase II trials for 
bone metastates in renal carcinoma patients.[60] However, a meta-analysis of its use in 
prostate cancer showed a significant decrease in CIBP and SRE with a delayed rise in PSA 
and bone alkaline phosphatase.[61]
Osteoprotegerin: OPG combines with RANKLto inhibit activation of RANK on 
osteoclasts, thereby preventing bone destruction induced by tumor cells.[3, 62] OPG has 
been shown to have inhibitory potential in breast cancer-induced bone destruction.[63]
Dasatinib: Src is a prototypic member of a nonreceptor tyrosine kinase family that is 
involved in various critical cellular functions, including cell morphology, cell growth, 
proliferation, differentiation, adhesion, migration and survival.[15] Dasatinib, a Src inhibitor, 
has been show to reduce metastatic potential and induce apoptosis in preclinical studies of 
pancreas, head and neck, and lung cancers.[15] Also, in vivo and in vitro studies show 
suppression of Src causes inhibition of breast cancer cells and reduced incidence of 
metastasis.[64]
Anti-NGF: New potential therapies in clinical phases of development target molecules like 
NGF, a molecule which is integrally involved in the upregulation, sensitization and 
disinhibition of neurotransmitters in the primary afferent nerves. Anti-NGF therapy could be 
effective in blocking CIBP due to NGF.[51]
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Resiniferatoxin (RTX): RTX is an ultrapotent agonist of the transient receptor potential 
vanilloid 1 (TRPV1) receptor. RTX acts on TRPV1 to allow for prolonged calcium influx, 
inducing cytotoxicity and death selectively in nociceptive fibres expressing TRPV1. 
Treatment with RTX has been shown to significantly improveme pain control in dogs with 
CIBP compared to standard of care analgesic therapy.[65]
Other therapies: Preclinical studies show TRPV1 and cannabinoid 2 receptor agonists 
could be used as adjuncts to ameliorate opioid side effects.[51] CXCL12/CXCR4 is found to 
play a central role in cancer cell proliferation, invasion and dissemination in various 
malignancies and is a potential drug-target in cancer management.[66]
III. RADIATION THERAPY (RT)
a. External Beam Radiation Therapy (EBRT)—EBRT is the most common form of 
RT used for palliation of CIBP. EBRT is produced in a linear accelerator which projects 
electrons onto a tungsten target, producing megavoltage photons directed towards bone 
lesions. The treatment usually takes 10–15 minutes per dose and relief can be acheived in 
50–80% patients. The acute side effects of radiation therapy are generally self-limiting and 
consist mainly of fatigue. Late side-effects in this patient group are relatively uncommon 
given the short life expectancy.[67] A systematic review of 24 randomized control trials 
(RCT) showed that single fraction administration of 8 Gy was statistically superior in pain 
response with minimal iatrogenic toxicity.[68] Evaluation of QoL following RT for patients 
with CIBP found improvement in symptoms and function using the Brief Pain Inventory 
score in all 17 studies included in the analysis.[69] Post-operative RT after surgical 
stabilization of metastatic bone disease has been found to be effective in local disease 
control. Along with bisphosphonates it might have the additional effect of delaying local 
progression.[70] Dexamethasone has been shown to reduce radiation-induced pain flare in 
the treatment of painful bone metastases in a double-blind randomized control trial.[71]
b. Stereotactic Body Radiation Therapy (SBRT)—SBRT uses image-guidance 
technology to deliver single or multiple fractions of high dose RT and can deliver nearly 2 to 
7-times the standard palliative dose.[72] A systematic review showed SBRT provided 
excellent local control with lower toxicity in patients with metastatic renal cell carcinoma.
[73] Although pain relief is higher in in SBRT, cost effectiveness of SBRT in comparison 
with EBRT in patients with a shorter expected survival (<11 months) remains contested.[74]
c. Role of Re-irradiation—Re-irradiation is effective and comparable to initial RT and 
should be recommended to patients suffering from ongoing CIBP irrespective of initial 
response to RT.[75]
d. Radioisotopes—Strontium-89 (S89) is a beta-emitting radioisotope with a half-life of 
50.5 days. Osteoblastic bone metastases have higher uptake than surrounding bone. 
Therefore S89 is used for the treatment of metastatic prostate or breast cancer with 
significant pain relief in 60–92%.[76]
Samarium-153 (Sm153) is a beta-emitter with a half-life of 1.9 days. It is chelated to 
ethylene diamine tetramethylene phosphate (EDTMP) which targets bone matrix as 
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pyrophosphate. It is used in various primary tumors and confers a superior survival in breast 
cancer patients at a higher dose.[76]
Other isotopes like Tin-117m (Sn117m), Radium-223 (Ra223), and Rhenium-186(Re186) are 
being tested in various clinical trials for CIBP in prostate and breast cancer. All of these 
therapies have distinct advantages over EBRT, which requires large areas of RT and is 
limited by toxicity.
e. MRI-guided Focused Ultrasound Ablation—Ultrasound ablation is a promising 
alternative therapy that was first tested in uterine fibroids. It uses non-invasive, non-ionizing 
ultrasound for pain palliation and tumor control. The interaction between the ultrasound 
beam and tissues results in a rise in cell temperature, leading to coagulative necrosis at a 
thermal range of 65–85 degrees C, which is limited to focal tissue volumes of 0.2–5mm3 and 
has negligible effect on surrounding tissue. The major advantages of this technology are the 
ability to be performed in an outpatient setting with three-dimensional MRI visualization for 
precise planning, continuous temperature mapping with MR thermometry, and immediate 
post-treatment assessment.[77, 78]
IV. INVASIVE PROCEDURES
a. Surgical Management—There is a significant palliative role for surgery in patients 
with CIBP in conjunction with other modalities. Surgical intervention is usually indicated 
for impending pathologic fractures, spine instability that threatens spinal cord function, or 
the development of nerve deficits. Based on pathology and patient prognosis, interventions 
may range from conservative measures to fracture stabilization with internal fixation or 
arthroplasty.[79] A systematic review assessed pain and functional outcomes following 
surgical management of metastases to the humerus, femur and pelvis and found pain relief in 
93, 91, and 93% of subjects respectively and improved function in 94, 89 and 94% of 
subjects respectively. In this study, there was a also substantial risk of perioperative 
complications (17%) and mortality (4%).[80]
Vertebroplasty is a technique involving fluoroscopic, percutaneous injection of 
polymethylmethacrylate and bone cement into the vertebral body for stabilization and pain 
relief in patients with compression fractures. Kyphoplasty involves placement of an 
inflatable balloon into the vertebral body with subsequent injection of bone cement. Both 
procedures can be performed under local or general anesthesia and are shown to provide 
effective and safe reduction in pain and improvement in mobility.[81] For palliative 
treatment of spinal metastases, the increasing use of minimally invasive techniques of tumor 
resection and decompression of neurologic elements have resulted in improved recovery 
with minimal morbidity and mortality.[82]
b. Intra-thecal analgesia—For patients requiring higher doses of opioids with 
unacceptable systemic side-effects, intra-thecal therapy may be a good alternative. Various 
intra-thecal analgesics including morphine sulphate, hydromorphone, and bupivacaine have 
proven efficacity.[83]
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c. Laser-induced thermotherapy—The use of Nd:YAG laser has been reported in a 
small case series as a treatment of treat spinal metastasis under CT—guidance. A total of 
1400–2600J energy delivered over 60–90 minutes has yielded 30–45% reductions in CIBP 
without complications.[84]
2.0 MUSCLE WEAKNESS IN CANCER
Cancer cachexia is a complex metabolic condition characterized by skeletal muscle wasting 
(with or without fat loss), anemia, reduced caloric intake, and altered immune function, 
which contributes to increased disability, fatigue, diminished QoL, and reduced survival.[85, 
86] Skeletal muscle wasting and resultant functional impairment significantly affect QoL. 
Cancer-related muscle loss is multifactorial, resulting in asthenia and functional impairment 
similar to that seen in patients with age-related sarcopenia as well that manifested by active 
muscle break-down.[87, 88] The common metabolic abnormalities to cancer cachexia and 
sarcopenia include altered hormone levels, elevated cytokines, increased insulin resistance, 
increased muscle proteolysis, elevated acute phase proteins, and altered nutrient utilization.
[87] Many experts believe, however, that muscle loss in cancer is a more active process, 
mediated by a number of pro-inflammatory cytokines, as well as members of the TGFβ-
superfamily including activins[89] and myostatin.[90, 91]
2.1 CLINICAL PRESENTATION AND ASSESSMENT OF CANCER INDUCED 
MUSCLE WEAKNESS (CIMW)
CIMW is one of the major symptoms of cancer cachexia. CT and DXA imagine can be used 
to quantify sarcopenia which correlates with clinical asthenia, fatigue, reduced tolerance to 
treatments, impaired QoL and reduced survival.[88]
2.2 PATHOPHYSIOLOGY OF CIMW
The skeletal muscle loss due to cachexia results from decreased protein anabolism, increased 
proteolysis, or a combination of both. The four major proteolytic pathways in skeletal 
muscle are:
1. The lysosomal system, which includes the cysteine proteases and cathepsins B, 
H, and, L, as well as aspartate protease cathepsin D, mainly degrades 
extracellular proteins and cell receptors.
2. The calcium-activated calpains I and II, which mainly cause tissue injury, 
necrosis and autolysis.
3. The ATP-dependent ubiquitin proteasome proteolytic pathway, which works with 
the calpain system to degrade myofilaments. This pathway plays a predominant 
role in degradation of myofibrillar proteins particularly in patients with a weight 
loss of >10%.[92]
4. The STAT3 pathway, which directly induces myocyte atrophy.[93, 94]. It induces 
muscle-specific E3 ubiquitin ligases [e.g. muscle atrophy F box (encoded by 
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MAFbx/atrogin-1) and muscle RING finger 1 (MuRF1)], which cause 
polyubiquitation of proteins targeted for degradation.[95]
Cachexia is known to feature tumor-induced activation of the host immune system and 
elevated proinflammatory cytokines IL-1β, IL-6, interferon(IFN-γ), TNF- α, and proteolysis 
inducing factor (PIF), all of which may primarily stimulate a catabolic state in skeletal 
muscle.[85, 96, 97] On a subcellular level, skeletal muscle weakness in cancer is due to a 
decrease in the number of strongly bound cross-bridges and a reduction in myosin-actin 
cross-bridge kinetics characterized by an increased myosin attachment time.[98] 
Chemotherapeutic agents like doxorubicin cause increased oxidative stress via formation of 
reactive oxygen species and activate caspases leading to loss of muscle mass and atrophy via 
the E3 ubiquitin-ligase proteasome pathway.[99] The mechanism of muscle wasting involves 
multiple host and tumor factors, decreased levels of testosterone and IGF-1, and decreased 
food intake contributing to both antianabolic and procatabolic processes.[85]
2.3 CURRENT THERAPEUTIC APPROACH TO CIMW
Unlike starvation, cancer cachexia does not respond to nutritional supplementation. 
Although caloric replacement up to 1.5mg/kg has shown some benefit in stabilizing weight,
[100] benefits of nutritional supplementation may be limited.[85] Essential amino acid 
(EAA) supplements, including ~2.5g of leucine, HMB supplements and vitamin D may 
improve muscle mass and function parameters.[101] Exercise therapy can help maintain or 
slow the loss of physical function.[101]
2.4 CURRENT AND POTENTIAL PHARMACOLOGIC THERAPIES FOR CIMW
5-HT3 antagonists
Mirtazapine and olanzapine provide 24-hour nausea control and increased appetite in cancer 
patients. They have the added benefit of controlling anxiety and aiding with better sleep.[96]
Megesterol acetate
This progetagen, combined with thalidomide, an anti-TNFα agent, has shown to 
significantly increase appetite with consequent improvement in body weight and QoL due to 
anti-inflammatory properties.[102] Megesterol carries an increased risk of 
thromboembolism, while thalidomide is known to cause birth defects in pregnant patients.
Enobosam
This nonsteroidal, selective androgen receptor modulators (SARMs), is in a phase III trial. 
Treatment with this medication has demonstrated increased lean body mass and is promising 
as an agent for the prevention and treatment of skeletal muscle wasting.[103] This 
medication prevents the need for non-selective systemic steroids, which carry significant 
side effects.
Ghrelin analogues
Anamorelin, is an oral ghrelin-receptor agonist with appetite-enhancing and anabolic effects, 
which has shown promising results in phase III trials.[104]
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Myostatin antagonists
Using a soluble receptor antagonist of myostatin (sActRIIB) in cachectic tumor-bearing 
animals has shown improvement in muscle weight and force through myostatin blockade.
[105]
β2 adrenoreceptor-selective agonist
Formoterol, promotes muscle growth and skeletal muscle hypertrophy in animal models. 
Espindolol, a nonspecific β1 and β2 adrenoreceptor antagonist with intrinsic 
sympathomimetic activity at the β2 adrenoreceptor has a novel anabolic-catabolic 
transforming property. These are prospective new drugs particularly beneficial for patients 
suffering from cancer cachexia with declined cardiac function.[106] Combination of 
sActRIIB with formoterol appears to be very promising in animal studies.[107]
3.0 ALTERATION OF BONE AND MUSCLE PHYSIOLOGY IN CANCER
CIMW is a major clinical problem in advanced stage cancer, and is usually associated with 
bone pain, fractures, hypercalcemia and nerve compression.[87] Bone and muscle function 
are interdependent physiologically. However, in cancer patients, accelerated bone resorption 
due to metastases increases “osteokines,” which significantly alter muscle function. 
Similarly, factors released from muscle can further exacerbate bone’s role in muscle 
dysfunction.[87] Normal excitation-contraction (E-C) coupling in skeletal muscle involves 
release of sequestered calcium from the sarcoplasmic reticulum into the cytoplasm via the 
activated ryanodine receptor/calcium release channel (RyR1), leading to calcium-dependent 
actin-myosin cross-bridging and muscle contraction.[108] Modifications to RyR1 from 
chronic oxidative stress causes disruption of RyR1 and its stabilizing subunit calstabim1, 
resulting in leaky calcium channels. In addition, TGFβ, a critical bone remodeling factor can 
mediate oxidative stress, and thereby further contribute to muscle dysfunction.[87]
3.1 Muscle Dysfunction Associated with Bone Metastasis in Cancer
Muscle secretes many factors, collectively called “myokines,” which affect other tissues. 
They include bone active molecules like IGF-1 and FGF-2, myostatin (also called growth 
differentiation factor 8 [GDF8])[109], and IL-6.[110–113] IGF-1 and FGF-2 stimulate bone 
formation,[114, 115] and myostatin deficiency increases bone density.[116, 117] Conversely, 
Indian hedgehog (Ihh) promotes myoblast survival and myogenesis in mouse and chick 
embryos.[87, 118] Preclinical mice model data show that predominantly osteolytic MDA-
MB-231 breast cancer, A549 lung cancer, PC3 prostate cancer and JJN3 multiple myeloma 
or mixed osteolytic/osteoblastic bone metastases result in lower muscle specific force, lower 
muscle strength, and RyR1 modifications consistent with leaky calcium channels regardless 
of weight loss or lower muscle mass as compared to non-tumor bearubg mice.[119] This 
suggets that there is a relationship between tumor-induced osteolysis-linked alterations in 
the bone microenvironment and skeletal muscle dysfunction. The RyR1 calcium release 
channel stabilizer Rycal (S107) improves the function of the leaky RyR1 channels by 
inhibiting oxidation-induced depletion of channel stabilizing subunit catstabin1 from the 
RyR1 complex, thereby stabilizing the closed state of the channels and preventing aberrant 
Milgrom et al. Page 12
Curr Osteoporos Rep. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
calcium leakage. Experiments of S107 function have shown improved forelimb grip strength 
in mice with breast cancer bone metastases. However, S107 does not affect development or 
progression of bone metastasis, tumor burden, body weight, muscle mass, or distribution of 
fat and lean mass compared to vehicle treated mice.[119] Thus, S107 treatment suggests that 
there is no direct correlation between bone destruction and reduced muscle function. Further 
studies are needed to assess the potential role of S107 in clinical practice to improve CIMW.
3.2 Bone Derived Factor(s) causing Muscle Dysfunction
Bone matrix stores many growth factors known to affect muscle, such as Activin A, TGFβ, 
IGF-1, and bone morphogenic protein 2 (BMP-2).[111] The high affinity Activin type 2 
receptor, ActRIIB, mediates signaling of a small group of TGFβ family members (Activin 
A, myostatin, GDF-11) and plays major role in regulating muscle mass.[113, 120, 121] In a 
murine model of cachexia, ActRIIB blockade prevents muscle wasting, induces muscle 
satellite cell mobilization and differentiation, and significantly prolongs survival.[122] 
However, it remains unclear from these studies if the effect is due to blockade of Activin A, 
myostatin or GDF-11 signaling due to receptor overlap.[111, 123]
During osteoclastic resorption, TGFβ is released from mineralized bone. In MDA-MB-231 
mice with bone metastases, TGFβ was shown to induce more SMAD3 phosphorylation in 
skeletal muscle compared to mice without metastases.[119, 124] TGFβ-1 receptor kinase 
inhibitor (SD-208), bisphosphonates (e.g. zoledronate - which inhibit osteoclastic resorption 
thereby lowering the release of TGFβ), and a pan-TGFβ neutralizing antibody (clone 1D11), 
have all shown a decrease in TGFβ in various experimental models, either in combination or 
alone. This in turn lowered skeletal muscle SMAD3 phosphorylation and preserved calstabin 
1 binding to RyR1 complex, resulting in improved muscle function. Combination therapy 
showed additional benefit by lowering tumor burden and number of osteoclasts. TGFβ 
inhibition improves muscle function, and bone-derived TGFβ contributes to CIMW, at least 
in part by inducing oxidation of RyR1.[119] TGFβ released from the bone matrix due to 
increased catabolism upregulates membrane protein Nox4 in the sarcoplasmic reticulum. 
Nox4 oxidizes the RyR1 channel and causes a calcium leak, lowering tetanic calcium, 
impairing muscle force production and contributing to muscle weakness in cancer with bone 
metastases. GKT137831m, a Nox1/Nox4 inhibitor, prevents skeletal muscle oxidation and 
nitrosylation of RyR1, restores calstabin binding, and improves extensor digitorum longus 
force in mice with MDA-MB-231 bone metastases as compared to vehicle treated mice; 
however, it did not block upstream TGFβ signaling and SMAD3 phosphorylation. In 
addition, it has no effect on osteolytic lesion size, muscle mass, body weight, or grip 
strength. Thus, targeting skeletal muscle weakness caused by the TGFβ-Nox4-RyR1 axis 
represents a novel therapeutic approach for patients.[125]
IGF-1 stimulates myogenic cell proliferation and differentiation[126, 127], while BMP-2 
signaling leads to muscle hypertrophy and thereby regulates muscle mass.[111] These are 
potential targets for restoring muscle mass. Additionally, vitamin D repletion may help 
functional status, as vitamin D deficiency studied in rodent models using vitamin D receptor 
knock-out (VDRKO) mice resulted in an increase in sinking episodes in a forced swim test.
[111, 128]
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MicroRNAs (miRNA) in vivo inhibit osteoclast activity and reduce osteolytic bone 
metastasis. Serum levels of soluble intracellular adhesion molecule (sICAM1) correlate with 
bone metastasis burden. These levels are affected by activation of NFκB signaling by bone 
metastatic cancer cells[129], and two osteoclast mRNAs, miR-16 and miR-378[130], which 
are elevated in osteoclast differentiation,. Hence, miRNAs could be potential therapeutic 
targets and clinical biomarkers of bone metastases.[130, 131]
CONCLUSION
The closely interrelated bone and muscle physiology is altered in cancer patients. The 
myokines secreted by skeletal muscle cells significantly impact the surrounding bone. 
Likewise, bone releases multiple growth factors during physiologic remodeling and affects 
muscle function. The metastasis of tumor cells to bone causes disruption between osteoclasts 
and osteoblasts along with various signaling pathways. The alteration of the 
microenvironment due to increased proinflammatory cytokines released from osteolytic 
bone resorption accelerates myofibrillar degradation and apoptosis. Clinically this manifests 
as a spectrum ranging from muscle weakness and fatigue to cachexia in skeletal muscle 
accompanied by bone pain, fractures, and neuropathy. Diagnosis is mainly clinical, while 
imaging and biochemical studies may aid in cases of challenging cases. Although the 
primary approach remains conservative, various therapeutic interventions have been 
formulated based on factors involving the metabolism of bone and skeletal muscle. Novel 
therapeutic agents targeting the molecular mechanism appear to be promising. Further 
studies are needed identify the exact mechanisms of the different cancers that metastasize to 
bone and interplay between bone and muscle to help develop effective targeted therapies.
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